International Society of Gastrointestinal Oncology
Hilton Crystal City
2399 Jefferson Davis Highway Arlington, VA 22202, United States (703) 418-6800
Arlington, VA , United States
 The 2012 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.
The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care. 

After attending this activity, the participant will demonstrate the ability to:
b 	Identify recent advances and innovations in the treatment of GI malignancies within the past 12 months
b 	Describe emerging evidence from current clinical trials that may impact treatment decision making in GI oncology
b 	Formulate a multi-modal approach to the treatment of hepatocellular carcinoma
b 	Analyze how recent clinical trial data demonstrate a significant survival benefit with a combination chemotherapy regimen in patients with metastatic pancreatic cancer
b 	Define which patients benefited the most based on the results of 2 large colon cancer trials demonstrated that the addition of cetuximab to chemotherapy improves outcomes for all patients with normal KRAS, regardless of BRAF status
b 	Discuss the multicenter trial results that demonstrate that sunitinib, a multi-targeted TKI, may delay disease progression in patients with pancreatic neuroendocrine tumors, and contribute to increased survival
b 	Name the prognostic value of 8 molecular markers on relapse-free survival and stages II and III colon cancer.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Johns Hopkins University School of Medicine and the International Society of Gastrointestinal Oncology. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. 

The Johns Hopkins University School of Medicine designates this live activity for a maximum of 15.0 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Creditâ„¢ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Creditâ„¢ from organizations accredited by the ACCME.

Schedule of Presentations:

Thursday, September 13, 2012
13:00:00 Introduction and ISGIO Presidential Inauguration Christopher Willett
13:05:00 Welcome From the President David H. Ilson
13:05:00 Session 1 | Esophageal/Gastric Cancer David H. Ilson
13:10:00 GE Junction and Esophageal Cancer: Treatment of Locally Advanced Disease
13:20:00 Chemotherapy Alone is Appropriate Preoperative Therapy
13:30:00 Chemotherapy and Radiation Therapy is Necessary Preoperative Therapy David H. Ilson
13:40:00 Q and A
13:50:00 Gastric Cancer: Postoperative Treatment of Locally Advanced Disease Chemotherapy and Radiation Are Needed in Resected Gastric Cancer Christopher Willett
14:00:00 Chemotherapy Alone is Appropriate Adjuvant or Neoadjuvant Therapy for Gastric Cancer Mitchell C Posner
14:10:00 Case Presentations/Panel Discussion
14:10:00 Q and A
14:15:00 Case 1: Advanced Disease | Second Line Therapy of Advanced Gastric Cancer Patient in Asia Takako E. Nakajima
14:30:00 Case 2: Stage IIB, Her2-Positive Gastric Cancer | What is appropriate adjuvant therapy: chemotherapy alone, chemotherapy plus radiotherapy, or either plus trastuzumab? Howard Safran
14:50:00 Panel Discussion
15:00:00 Proffered Papers
15:20:00 Break/Poster Session
15:30:00 Session 2 | Pancreatic Cancer Michael A. Choti
15:35:00 Update on Clinical Trials in Adjuvant Therapy for Pancreatic Adenocarcinoma Robert J. Mayer
15:55:00 Q and A
16:00:00 Multidisciplinary Management of Locally Advanced and Borderline Disease Jason B. Fleming
16:20:00 Q and A
16:25:00 Case Presentation/Panel Discussion
16:40:00 Case 1: Resectable Distal Pancreatic Cancer Andrew M. Lowy
16:55:00 Case 2: Localized Head of the Pancreatic Cancer
17:05:00 Case 3: Locally Advanced Pancreatic Cancer Joseph M. Herman
17:15:00 Panel Discussion
17:25:00 Proffered Papers
Friday, September 14, 2012
07:55:00 Session 3 | Advanced Colon Cancer Howard S. Hochster
08:00:00 Debate: Biologics in First-Line Therapy
08:10:00 Bevacizumab Axel Grothey
08:20:00 EGFR inhibitors Howard S. Hochster
08:30:00 Asian Approach to Advanced Colorectal Cancer (First-Line)
08:45:00 Q and A
09:00:00 Maintenance Therapy with Biologics
09:25:00 Case Presentations/Panel Discussion | Case 1: Rectal Cancer with Resectable Liver Metastases Brian G. Czito
09:25:00 Q and A
09:50:00 Panel Discussion
09:55:00 Proffered Papers
10:05:00 Break/Poster Session
10:15:00 Session 4 | Hot Topics in Gastrointestinal Oncology Christopher Willett
10:20:00 Genomics in GI Cancer
10:40:00 Q and A
10:45:00 Infection in GI Cancer: Helicobacter. Pylori Juanita L. Merchant
11:05:00 Q and A
11:10:00 Screening for Colorectal Cancer with Emphasis on Stool DNA David A. Ahlquist
11:30:00 Q and A
11:35:00 GI Cooperative Groups Daniel G. Haller
11:55:00 Q and A
12:00:00 CME Satellite Symposium and Lunch
14:00:00 Break/Poster Session
14:10:00 Session 5 | Localized/Adjuvant Colorectal Cancer Axel Grothey
14:15:00 Molecular Markers, Molecular Signatures and Treatment Decision in Stage II Colon Cancer Daniel J. Sargent
14:35:00 Q and A
14:40:00 Asian Approach to Adjuvant Therapy in Colon Cancer
15:00:00 Q and A
15:05:00 Laparoscopic Surgery of Rectal Cancer: Are We There Yet? Heidi Nelson
15:25:00 Q and A
15:30:00 Case Presentations/Panel Discussion
15:40:00 Case 1: Elderly Patient with Stage III Colon Cancer Joleen M. Hubbard
15:50:00 Case 2: Radiation Therapy in Rectal Cancer Christopher Willett
16:00:00 Panel Discussion
16:15:00 Proffered Papers
Saturday, September 15, 2012
07:55:00 Session 6 | Neuroendocrine Tumors (NET) Jonathan R. Strosberg
08:00:00 Advances in Treatment of Pancreatic Neuroendocrine Tumors Jonathan R. Strosberg
08:20:00 Q and A
08:25:00 Transarterial Embolic Therapy for Liver-Predominant NETs: Bland vs. Chemoembolization vs. Radioembolization David R Liu
08:45:00 Q and A
08:50:00 Updates on Pathologic Classification and Grading of NETs David S. Klimstra
09:10:00 Q and A
09:15:00 Case Presentations/Panel Discussion
09:25:00 Case 1: Small Bowel Carcinoid with Progressive Bilobar Hepatic Metastases Jonathan R. Strosberg
09:35:00 Case 2: Metastatic Non-Functioning Pancreatic Neuroendocrine Tumor George A. Fisher
09:50:00 Panel Discussion
10:00:00 Proffered Papers
10:20:00 Break/Poster Session
10:30:00 Session 7 | Hepatobiliary Cancer Mary F. Mulcahy
10:35:00 Systemic Therapy for Advanced HCC: Beyond Sorafenib Rebecca A. Miksad
10:55:00 Q and A
11:00:00 Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis and Therapy Ghassan K Abou-Alfa
11:20:00 Q and A
11:25:00 Update in Diagnostic and Therapeutic Interventions for Biliary Duct Cancer Sri Komanduri
11:45:00 Q and A
11:45:00 Case Presentations/Panel Discussion
11:50:00 Case 1: Small HCC in Patient with Viral Hepatitis Weijing Sun
12:10:00 Case 2: Localized Unresectable HCC: Japanese Approach
12:15:00 Panel Discussion
12:35:00 Proffered Papers
12:45:00 Summary David Wilson
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.